GCA Altium advises Quadriga Capital on its acquisition of GBA Gesellschaft für Bioanalytik from Adiuva Capital
GBA Gesellschaft für Bioanalytik mbH (“GBA”) has, since its inception, developed organically and inorganically into one of Germany’s leading laboratory service providers. The company engages in food, environmental and pharma laboratory analysis and testing services, operating in 11 locations across Germany and Austria.
As part of GBA’s further expansion strategy, Quadriga Capital Private Equity Fund IV L.P. acquired the shares held by Adiuva Capital. CEO Manfred Giesecke will stay significantly invested in GBA, along with the remaining management team which has acquired a minority stake.
All involved parties agreed not to disclose the terms of the transaction, which is still subject to regulatory approval.
“GBA is a high quality business that offers very strong growth fundamentals paired with extremely high quality standards, strongly valued by its customers. We are delighted to provide supporting advice to GBA’s management team in its national and international roll-out”, commented Dr. Alexander Friedrich, Partner of Quadriga Capital Beteiligungsberatung GmbH, who acts as an Investment Advisor.
Madeleine Jahr, Director at GCA Altium, added: “It has been an absolute pleasure to advise Quadriga Capital on this high profile transaction. GBA enjoys an outstanding reputation in the market and together with Quadriga Capital, we have every confidence that the company is in an excellent position to continue to thrive over the coming years.”
This latest transaction sees GCA Altium build on its leading position in international business services advisory, having completed 21 transactions in this sector since the start of 2015.